Fangzhou H1 2026 Results AI Chronic Care
Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026
The results show continued growth in revenue and profit, reflecting successful execution of the AI-driven chronic care strategy. The stock closed unchanged at HK$0.69, indicating a muted immediate market reaction, but the expansion of partnerships and medical insurance integration could support long-term growth.
Fangzhou (HKEX: 06086), a leading AI-driven Internet healthcare company, announced its interim results for the six months ended June 30, 2026. Revenue increased 22.2% year-on-year to RMB 1.8245 billion, while adjusted net profit rose 6.4% to RMB 18.7 million. The company continued to execute its 'AI + chronic care' strategy, expanding its user base to over 59.8 million registered users and 14.7 million average monthly active users, and growing its physician network to 282,000. Fangzhou also expanded partnerships with pharmaceutical companies including Youcare Pharmaceutical and Tenry Pharma, and completed agreements and system integration for medical insurance services across China — Guangdong Province. The company plans to further upgrade its large-model and AI-agent capabilities in the second half of 2026, positioning itself as a 'full-lifecycle personal health service partner' aligned with China's Healthy China 2030 initiative.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard